ArticleJournal of molecular histology2026
DLAT/DLD-dependent cuproptosis disrupts osteoblast-macrophage crosstalk through mtDNA-associated STING signaling under delayed-healing-like inflammatory-hypoxic conditions.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Impaired fracture repair is associated with sustained inflammation, mitochondrial dysfunction, and disrupted osteoblast-macrophage communication. Cuproptosis involves copper-dependent aggregation of lipoylated mitochondrial proteins and loss of iron-sulfur proteins, suggesting a potential connection between mitochondrial injury and osteoimmune dysfunction. This study investigated this relationship in an in vitro inflammatory-hypoxic model. Human hFOB 1.19 osteoblasts and THP-1-derived macrophages were studied under delayed-healing-like stress (DHS; 1% O₂ with TNF-α/IL-1β). Elesclomol-Cu (ES-Cu) served as a mechanistic probe, while tetrathiomolybdate (TTM) and DLAT/DLD depletion were used to investigate copper-dependent injury. Assessments included copper accumulation, cuproptosis-associated markers, mitochondrial function, mtDNA abundance, and STING-associated signaling. Conditioned-medium transfer and three-dimensional fibrin co-culture examined inflammatory responses and osteogenic differentiation. DNase treatment and macrophage STING depletion assessed contributions from extracellular DNA and STING. DHS increased intracellular copper (P = 0.0009) and produced modest cuproptosis-associated changes, which were more pronounced following ES-Cu addition. TTM or DLAT/DLD depletion attenuated injury, mitochondrial dysfunction, and mtDNA accumulation. Conditioned medium from injured osteoblasts increased macrophage CD86 positivity and inflammatory cytokine secretion while reducing CD206 positivity. DNase treatment or macrophage STING depletion attenuated inflammatory responses. Macrophage-conditioned medium subsequently suppressed ALP activity, mineralization, and osteogenic gene expression in recipient osteoblasts. These endpoints improved following donor-cell interventions or macrophage STING depletion. Three-dimensional co-culture showed corresponding changes. The findings support a model linking experimentally induced copper-dependent osteoblast injury under DHS with mtDNA-associated STING signaling, macrophage inflammatory responses, and impaired osteogenic differentiation. They do not establish mtDNA-specific cGAS activation or cuproptosis-specific effects of DLAT/DLD depletion, and residual treatment carryover remains unresolved. Validation beyond these cell-line systems is required before extending the findings to clinical delayed fracture healing.
Indexed as
Identifiers
43002323What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.